Report Company Directory
- Aptorum Group Announces Completion of End of Phase 1 (EOP1) Meeting with US FDA on its SACT-1, a Repurposed Small Molecule Drug Targeting Neuroblastoma by BusinessWire
- Aptorum Group Announces Completion of Pre-IND Discussions with US FDA on its ALS-4, a First-in-Class Small Molecule Drug Targeting Methicillin Resistant Staphylococcus Aureus by BusinessWire
- Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in China by BusinessWire
- Aptorum Group Limited to Hold Special Extraordinary Meeting of Shareholders on February 21, 2023 by BusinessWire
- Aptorum Group Announces 1-for-10 Reverse Stock Split by BusinessWire
- Aptorum Group annonce la publication d’un document co-écrit sur sa technologie PathsDx, un flux rapide de séquençage métagénomique objectif à faible profondeur pour le diagnostic des maladies infectieuses basé... by BusinessWire
- Aptorum Group Announces Publication of a Co-authored Paper on its PathsDx Technology - a Rapid-Turnaround Low-Depth Unbiased Metagenomics Sequencing Workflow for Liquid Biopsy based Diagnosis of Infectious Diseases on Illumina Platforms by BusinessWire
- Aptorum Group reçoit l'autorisation de Santé Canada pour entamer un essai clinique de Phase 1 sur l'ALS-4, un médicament à petite molécule destiné à traiter les infections à staphylocoque doré (Staphylococcus aureus), y compris le staphylocoque... by BusinessWire
- Aptorum Group Receives Clearance from Health Canada to Initiate a Phase 1 Clinical Trial for ALS-4, a Small Molecule Drug for Infections Caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA) by BusinessWire
- Aptorum Group annonce la présentation des demandes d'essai clinique pour l'ALS-4, un médicament à petites molécules administré par voie orale pour le traitement des infections causées par le Staphylococcus aureus... by BusinessWire